Literature DB >> 28921801

Complications, symptoms, quality of life and pregnancy in cholestatic liver disease.

Kais Zakharia1, Anilga Tabibian2, Keith D Lindor3,4, James H Tabibian5.   

Abstract

Cholestatic liver diseases (CLDs) encompass a variety of disorders of bile formation and/or flow which generally result in progressive hepatobiliary injury and ultimately end-stage liver disease. Many patients with CLD are diagnosed between the ages of 20-50 years, a particularly productive period of life professionally, biologically and in other respects; it is not surprising, thus, that CLD is often associated with impaired health-related quality of life (HRQOL) and uncertainty regarding implications for and outcomes of pregnancy. Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are the most prominent CLDs, both having considerable morbidity and mortality and representing major indications for liver transplantation. These disorders, as a consequence of their complications (eg ascites, hepatic osteodystrophy), associated conditions (eg inflammatory bowel disease) and symptoms (eg pruritus and fatigue), can significantly impair an array of domains of HRQOL. Here we review these impactful clinical aspects of PSC and PBC as well as the topics of fertility and pregnancy.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biliary tract diseases; pharmacotherapy; primary biliary cholangitis; primary sclerosing cholangitis; pruritus

Mesh:

Year:  2017        PMID: 28921801     DOI: 10.1111/liv.13591

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

1.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

2.  Increased butyrate priming in the gut stalls microbiome associated-gastrointestinal inflammation and hepatic metabolic reprogramming in a mouse model of Gulf War Illness.

Authors:  Ratanesh Kumar Seth; Diana Kimono; Firas Alhasson; Sutapa Sarkar; Muayad Albadrani; Stephen K Lasley; Ronnie Horner; Patricia Janulewicz; Mitzi Nagarkatti; Prakash Nagarkatti; Kimberly Sullivan; Saurabh Chatterjee
Journal:  Toxicol Appl Pharmacol       Date:  2018-05-09       Impact factor: 4.219

3.  Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

Review 4.  Importance of fatigue and its measurement in chronic liver disease.

Authors:  Lynn H Gerber; Ali A Weinstein; Rohini Mehta; Zobair M Younossi
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

5.  Inflammatory bowel diseases: time of diagnosis, environmental factors, clinical course, and management - a follow-up study in a private inflammatory bowel disease center (2003-2017).

Authors:  D B Cury; R Oliveira; M S Cury
Journal:  J Inflamm Res       Date:  2019-05-28

6.  Rare but heard: using asynchronous virtual focus groups, interviews and roundtable discussions to create a personalised psychological intervention for primary sclerosing cholangitis: a protocol.

Authors:  Veronica Ranieri; Eilis Kennedy; Martine Walmsley; Doug Thorburn; Kathy McKay
Journal:  BMJ Open       Date:  2019-10-02       Impact factor: 2.692

7.  Quality of life in primary sclerosing cholangitis: a systematic review.

Authors:  Elena Marcus; Paddy Stone; Anna-Maria Krooupa; Douglas Thorburn; Bella Vivat
Journal:  Health Qual Life Outcomes       Date:  2021-03-20       Impact factor: 3.186

8.  Primary biliary cholangitis first demonstrated in pregnancy: a case report.

Authors:  Daniela Melo; Ana Luísa Areia; Paulo Moura
Journal:  J Med Case Rep       Date:  2022-01-31

9.  Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases.

Authors:  Wenkuan Li; Jawaher Abdullah Alamoudi; Nagsen Gautam; Devendra Kumar; Macro Olivera; Yeongjin Gwon; Sandeep Mukgerjee; Yazen Alnouti
Journal:  Int J Hepatol       Date:  2022-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.